CNS – Child Neurology Society

Oct 14 – 17
Montreal, Canada

Tourette Syndrome

Long-Term Safety and Effect of Ecopipam, a Selective Dopamine D1 Receptor Antagonist, in Children, Adolescents, and Adults With Tourette Syndrome

Authors:
Donald L. Gilbert, Kevin J. Black, Katie Kompoliti, Patricia M. Rice, John A. Flatt, George B. Karkanias, Stephen P. Wanaski, Timothy M. Cunniff,  Kinga K. Tomczak

Download the poster

Ecopipam Does Not Negatively Impact Weight, Metabolic Parameters, or Electrocardiogram Measurements or Induce Movement Disorders in Individuals With Tourette Syndrome

Authors:
Tamar C. Katz,  Erica Greenberg, Donald L. Gilbert, John A. Flatt, MD; George B. Karkanias, Frederick E. Munschauer,  Stephen P. Wanaski, Timothy M. Cunniff, Kinga K. Tomczak

Download the poster

Ecopipam—Evidence for Its Lack of Abuse Potential Based on Evaluation in an 8-Factor Analysis

Authors:
Stephen P. Wanaski, Timothy M. Cunniff, George B. Karkanias, John A. Flatt, Sharon L. Smith,  Jane Gosden, David J. Heal

Download the poster

Ecopipam, a First-in-Class, Selective Dopamine D1 Receptor Antagonist, Is Noncarcinogenic in Rodents

Authors:
Stephen P. Wanaski, Timothy M. Cunniff, George B. Karkanias,  Duane A. Belote, Andrew Suttie, Alok K. Sharma, Shana R. Dalton

Download the poster

Safety and Effect of Ecopipam During the First 8 Weeks of Tourette Syndrome/Disorder Treatment: A Post Hoc Analysis

Authors:
Kinga K. Tomczak, Tamar C. Katz, John A. Flatt, George B. Karkanias, Stephen P. Wanaski, Timothy M. Cunniff, Donald L. Gilbert

Download the poster

Presence of Common Psychiatric Diagnoses Did Not Impact the Efficacy or Safety of Ecopipam in Individuals With Tourette Syndrome/Disorder

Authors:
Joseph F McGuire, John A. Flatt, George B. Karkanias, Frederick E. Munschauer, Timothy M. Cunniff, Stephen P. Wanaski, Erica Greenberg

Download the poster